These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 8999135)

  • 1. [Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1996 Sep; 71(9):531-5. PubMed ID: 8999135
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (1) Continuous positive cases (failure of the initial chemotherapy)].
    Sakatani M
    Kekkaku; 1996 Sep; 71(9):544-7. PubMed ID: 8999139
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (2) Multi-drug chemotherapy for initial cases on trial].
    Tanaka E
    Kekkaku; 1996 Sep; 71(9):547-9. PubMed ID: 8999140
    [No Abstract]   [Full Text] [Related]  

  • 5. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
    Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
    Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for development of new antimycobacterial drugs.
    Tomioka H
    J Infect Chemother; 2000 Mar; 6(1):8-20. PubMed ID: 11810525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antimycobacterial agents.
    Cynamon MH; Klemens SP
    Clin Chest Med; 1989 Sep; 10(3):355-64. PubMed ID: 2505963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The bacteriology of tuberculosis and non-tuberculosis mycobacterial infections].
    Wyplosz B; Truffot-Pernot C; Robert J; Jarlier V; Grosset J
    Rev Mal Respir; 1997 Dec; 14 Suppl 5():S33-48. PubMed ID: 9496590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
    Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
    J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective.
    Benson CA
    Res Microbiol; 1996; 147(1-2):16-24. PubMed ID: 8761717
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of mycobacterial infections.
    Davidson PT
    Bull Int Union Tuberc Lung Dis; 1988 Dec; 63(4):23-5. PubMed ID: 3228601
    [No Abstract]   [Full Text] [Related]  

  • 12. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
    Bermudez LE; Kolonoski P; Petrofsky M; Wu M; Inderlied CB; Young LS
    J Infect Dis; 2003 Jun; 187(12):1977-80. PubMed ID: 12792877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
    Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones.
    Watanabe M; Hasegawa N; Ishizaka A; Asakura K; Izumi Y; Eguchi K; Kawamura M; Horinouchi H; Kobayashi K
    Ann Thorac Surg; 2006 Jun; 81(6):2026-30. PubMed ID: 16731124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro anti-MAC activities of new quinolones in focus (1)].
    Tsuyuguchi K
    Kekkaku; 1996 Sep; 71(9):536-7. PubMed ID: 8999136
    [No Abstract]   [Full Text] [Related]  

  • 16. [In vitro anti-MAC activities of new quinolones in focus (2)].
    Kawahara S; Eirei J
    Kekkaku; 1996 Sep; 71(9):537-9. PubMed ID: 8999137
    [No Abstract]   [Full Text] [Related]  

  • 17. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
    Sato K; Tomioka H
    Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activity of antibiotics against pigmented and unpigmented variants of Mycobacterium avium-intracellulare].
    Gevaudan MJ; Bollet C; Mallet MN; de Micco P
    Pathol Biol (Paris); 1991 May; 39(5):429-35. PubMed ID: 1652731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Susceptibility to rifabutin and novel fluoroquinolones in Mycobacterium avium complex isolates from patients with sputum culture-positive pulmonary disease who are undergoing standard chemotherapy].
    Tateishi Y; Motone M; Yoshimura K; Miki M; Miki K; Kitada S; Hashimoto H; Hiraga T; Maekura R
    Nihon Kokyuki Gakkai Zasshi; 2010 Nov; 48(11):797-802. PubMed ID: 21141056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of nontuberculous mycobacterial disease.
    Griffith DE
    Curr Opin Infect Dis; 2007 Apr; 20(2):198-203. PubMed ID: 17496580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.